On September 23, LEADS BIOLABS-B rose 5.54% in regular trading, trading at approximately 57.15 HKD/share, with turnover of approximately 72.10 million HKD. The rally was driven by the continued digestion of a key clinical milestone announcement and a technical rebound from the prior session's sharp sell-off.
On the news front, the company previously announced that the pivotal registrational Phase IIb study of its core drug Wellixin (Opamtistomig, a PD-L1/4-1BB bispecific antibody) as monotherapy for advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) was selected as a Late-Breaking Abstract (LBA) at ESMO 2026, with a proffered oral presentation scheduled for October 26. The LBA designation signals breakthrough clinical value and the potential to reshape current treatment paradigms. The drug's NDA was accepted by China's NMPA in August and granted priority review.
The prior trading session saw a 5.59% decline triggered by the disclosure that share incentive platform Nanjing Lizhi sold approximately 859,100 shares at an average price of 63.69 HKD, sparking profit-taking pressure after a rally fueled by Morgan Stanley's upgrade to Overweight and positive WCLC data catalysts. The current session's rebound reflects the market re-pricing the ESMO milestone against the oversold condition.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments